ウイルスベクターとプラスミドDNA製造の世界市場レポート 2025年

ウイルスベクターとプラスミドDNA製造市場規模は、今後数年で飛躍的な成長が見込まれます。2029年には複合年間成長率（CAGR）23.5％で165億2,000万米ドルに成長します。予測期間の成長は、遺伝子治療数の増加、市場参入企業の増加、感染症や遺伝性異常の発生率の増加、細胞・遺伝子治療研究分野への投資の増加、対象疾患や疾病の発生率の増加に起因しています。予測期間における主な動向としては、技術の進歩、遺伝子治療の進歩、先端技術の採用、シングルユース技術の採用、ワクチン技術の進歩などが挙げられます。

遺伝子治療の増加は、ウイルスベクターとプラスミドDNA製造市場の成長を押し上げると予測されています。遺伝子治療は、疾病の治療や予防のために人の細胞内の遺伝物質を改変することを含みます。この分野は、バイオテクノロジーの研究開発への投資が増加し、様々な疾患の根底にある遺伝的・細胞的メカニズムの理解が深まったことで進展しています。ウイルスベクターやプラスミドDNAは、治療用遺伝子を患者の細胞内に送り込み、分子レベルでの遺伝性疾患の治療を可能にするために極めて重要です。例えば、米国の非営利団体である米国遺伝子細胞治療学会（American Society of Gene &Cell Therapy）は、2023年第3四半期に第III相臨床試験中の遺伝子治療薬の数が10％増加したと報告し、2022年第3四半期以来の四半期ごとの増加を記録しました。この遺伝子治療の成長がウイルスベクターとプラスミドDNA製造の需要を牽引しています。

ウイルスベクターとプラスミドDNA製造市場の主な企業は、生産能力を拡大し、技術力を強化し、遺伝子治療の世界の開発と商業化を加速するために、戦略的パートナーシップを追求しています。このような提携により、各社はリソースやインフラを共有し、遺伝子治療の需要増に対応する生産能力を高めています。例えば、2024年6月、米国の前臨床・臨床受託研究機関であるチャールズ・リバー・ラボラトリーズ・インターナショナル・インクと、ドイツのマックス・デルブルック・センターからスピンオフしたキャプテンTセルは、プラスミドDNAとレトロウイルスベクターの生産プログラム契約を締結しました。このパートナーシップにより、キャプテンTセルは確立されたCDMO（開発製造受託機関）能力とアドバイザリーサービスを利用できるようになり、固形がんを標的とする新規TCR-T細胞療法の前臨床研究から臨床試験への進行を加速させることを目指します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウイルスベクターとプラスミドDNA製造PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のウイルスベクターとプラスミドDNA製造市場：成長率分析
• 世界のウイルスベクターとプラスミドDNA製造市場の実績：規模と成長, 2019-2024
• 世界のウイルスベクターとプラスミドDNA製造市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウイルスベクターとプラスミドDNA製造総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウイルスベクターとプラスミドDNA製造市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラスミドデオキシリボ核酸（DNA）
• ウイルスベクター
• 非ウイルスベクター
• 世界のウイルスベクターとプラスミドDNA製造市場事業規模別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• 臨床
• 商業用
• 世界のウイルスベクターとプラスミドDNA製造市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍性疾患
• 希少疾患
• 神経疾患
• 感覚障害
• 代謝障害
• 筋骨格系障害
• 血液疾患
• 免疫疾患
• その他の障害
• 世界のウイルスベクターとプラスミドDNA製造市場：応用分野別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子治療
• 細胞療法
• ワクチン
• 世界のウイルスベクターとプラスミドDNA製造市場メーカー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 社内メーカー
• 契約製造組織
• 世界のウイルスベクターとプラスミドDNA製造市場プラスミドデオキシリボ核酸（DNA）の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直鎖プラスミドDNA
• 環状プラスミドDNA
• 高コピープラスミドDNA
• 低コピープラスミドDNA
• 世界のウイルスベクターとプラスミドDNA製造市場ウイルスベクターのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• アデノウイルスベクター
• レンチウイルスベクター
• アデノ随伴ウイルスベクター（AAV）
• レトロウイルスベクター
• 世界のウイルスベクターとプラスミドDNA製造市場非ウイルスベクターの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポソームベースのベクター
• ポリマーベースのベクター
• ナノ粒子ベースのベクター
• 電気穿孔法に基づくベクター

第7章 地域別・国別分析

• 世界のウイルスベクターとプラスミドDNA製造市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウイルスベクターとプラスミドDNA製造市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウイルスベクターとプラスミドDNA製造市場：競合情勢
• ウイルスベクターとプラスミドDNA製造市場：企業プロファイル
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Catalent Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Revvity Inc.
• Wuxi Biologics Inc.
• BioMarin Pharmaceutical
• FUJIFILM Diosynth Biotechnologies
• Miltenyi Biotec GmbH
• Aldevron LLC
• Takara Bio Inc.
• Poseida Therapeutics Inc.
• RegenxBio Inc.
• Cobra Biologics
• Finvector Vision Therapies Limited
• Batavia Biosciences B.V.
• uniQure N.V.
• Addgene Inc.
• BioNTech IMFS GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウイルスベクターとプラスミドDNA製造市場2029：新たな機会を提供する国
• ウイルスベクターとプラスミドDNA製造市場2029：新たな機会を提供するセグメント
• ウイルスベクターとプラスミドDNA製造市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Viral vectors and plasmid DNA manufacturing involves the production of viral vectors and plasmid DNA, which are crucial for gene therapy, vaccine development, and genetic research. This process includes complex biotechnological techniques to ensure the safety, efficacy, and consistency of the products.

Key products in the viral vectors and plasmid DNA manufacturing market include plasmid DNA, viral vectors, and non-viral vectors. Plasmid DNA consists of small, circular DNA molecules utilized in genetic research and biotechnology. These products are manufactured at various scales-preclinical, clinical, and commercial. The market addresses a range of therapeutic areas, including oncology, rare diseases, neurological and sensory disorders, metabolic and musculoskeletal disorders, blood disorders, and immunological disorders. These products are used in gene therapies, cell therapies, and vaccines. Manufacturing is conducted by both in-house teams and contract manufacturing organizations (CMOs).

The viral vectors and plasmid DNA manufacturing market research report is one of a series of new reports from The Business Research Company that provides viral vectors and plasmid DNA manufacturing market statistics, including the viral vectors and plasmid DNA manufacturing industry global market size, regional shares, competitors with viral vectors and plasmid DNA manufacturing market share, detailed viral vectors and plasmid DNA manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the viral vectors and plasmid DNA manufacturing industry. These viral vectors and plasmid DNA manufacturing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The viral vectors and plasmid dna manufacturing market size has grown exponentially in recent years. It will grow from $5.75 billion in 2024 to $7.11 billion in 2025 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to demand for personalized medicine, growth in vaccine development, availability of funding for gene therapy development, efficiency of viral vectors in gene therapy delivery, and potential applications in novel drug delivery approaches.

The viral vectors and plasmid dna manufacturing market size is expected to see exponential growth in the next few years. It will grow to $16.52 billion in 2029 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing number of gene therapies, growing number of market participants, increasing rates of infectious illnesses and hereditary abnormalities, increasing investments in cell and gene therapy research space, and growing occurrence of target disorders and diseases. Major trends in the forecast period include technological advancements, advancements in gene therapy, adoption of advanced technologies, adoption of single-use technologies, and advancement in vaccine technology.

The rising number of gene therapies is anticipated to boost the growth of the viral vectors and plasmid DNA manufacturing market. Gene therapy involves modifying genetic material within a person's cells to treat or prevent disease. This field is advancing due to increased investment in biotechnology research and development and a deeper understanding of genetic and cellular mechanisms underlying various conditions. Viral vectors and plasmid DNA are crucial for delivering therapeutic genes into patients' cells, enabling the treatment of genetic disorders at a molecular level. For example, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported a 10% increase in the number of gene therapies in Phase III clinical trials during Q3 2023, marking the first quarterly rise since Q3 2022. This growth in gene therapies is driving demand for viral vectors and plasmid DNA manufacturing.

Key companies in the viral vectors and plasmid DNA manufacturing market are pursuing strategic partnerships to expand production capacities, enhance technological capabilities, and accelerate the global development and commercialization of gene therapies. These collaborations allow companies to share resources and infrastructure, boosting production capacity to meet the increasing demand for gene therapies. For instance, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, and Captain T Cell, a spin-off from Germany's Max Delbruck Center, established a production program agreement for plasmid DNA and retrovirus vectors. This partnership grants Captain T Cell access to established contract development and manufacturing (CDMO) capabilities and advisory services, aiming to accelerate the progression from preclinical research to clinical trials for a novel TCR-T cell therapy targeting solid tumors.

In December 2023, Polyplus, a France-based biochemistry laboratory, acquired Xpress Biologics for an undisclosed amount. This acquisition is expected to enhance Polyplus' product portfolio and strengthen its capabilities in plasmid DNA production, which is vital for gene and cell therapies. Xpress Biologics, based in Belgium, specializes in producing plasmid DNA and proteins using microbial expression systems, and this acquisition will solidify Polyplus' position in the expanding gene therapy market.

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Astellas Pharma Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., BioMarin Pharmaceutical, FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the viral vectors and plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral vectors and plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as process development, cell line development, and analytical and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vectors and plasmid DNA manufacturing market also includes sales of bioreactors, cell culture systems, reagents and consumables. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Vectors And Plasmid DNA Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral vectors and plasmid dna manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral vectors and plasmid dna manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral vectors and plasmid dna manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Plasmid Deoxyribonucleic Acid (DNA); Viral Vector; Non-Viral Vector
• 2) By Scale Of Operation: Preclinical; Clinical; Commercial
• 3) By Therapeutic Area: Oncological Disorders; Rare Diseases; Neurological Disorders; Sensory Disorders; Metabolic Disorders; Musculoskeletal Disorders; Blood Disorders; Immunological Disorders; Other Disorders
• 4) By Application Area: Gene Therapies; Cell Therapies; Vaccines
• 5) By Type Of Manufacturer: In-house Manufacturers; Contract Manufacturing Organizations
• Subsegments:
• 1) By Plasmid Deoxyribonucleic Acid (DNA): Linear Plasmid DNA; Circular Plasmid DNA; High-Copy Plasmid DNA; Low-Copy Plasmid DNA
• 2) By Viral Vector: Adenoviral Vectors; Lentiviral Vectors; Adeno-Associated Viral Vectors (AAV); Retroviral Vectors
• 3) By Non-Viral Vector: Liposome-Based Vectors; Polymer-Based Vectors; Nanoparticle-Based Vectors; Electroporation-Based Vectors
• Companies Mentioned: Merck KGaA; Thermo Fisher Scientific Inc.; Astellas Pharma Inc.; Lonza Group AG; Catalent Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Vectors And Plasmid DNA Manufacturing Market Characteristics

3. Viral Vectors And Plasmid DNA Manufacturing Market Trends And Strategies

4. Viral Vectors And Plasmid DNA Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Viral Vectors And Plasmid DNA Manufacturing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Vectors And Plasmid DNA Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Vectors And Plasmid DNA Manufacturing Market Growth Rate Analysis
• 5.4. Global Viral Vectors And Plasmid DNA Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Vectors And Plasmid DNA Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Vectors And Plasmid DNA Manufacturing Total Addressable Market (TAM)

6. Viral Vectors And Plasmid DNA Manufacturing Market Segmentation

• 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmid Deoxyribonucleic Acid (DNA)
• Viral Vector
• Non-Viral Vector
• 6.2. Global Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.3. Global Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncological Disorders
• Rare Diseases
• Neurological Disorders
• Sensory Disorders
• Metabolic Disorders
• Musculoskeletal Disorders
• Blood Disorders
• Immunological Disorders
• Other Disorders
• 6.4. Global Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Application Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapies
• Cell Therapies
• Vaccines
• 6.5. Global Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Type Of Manufacturer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In-house Manufacturers
• Contract Manufacturing Organizations
• 6.6. Global Viral Vectors And Plasmid DNA Manufacturing Market, Sub-Segmentation Of Plasmid Deoxyribonucleic Acid (DNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Linear Plasmid DNA
• Circular Plasmid DNA
• High-Copy Plasmid DNA
• Low-Copy Plasmid DNA
• 6.7. Global Viral Vectors And Plasmid DNA Manufacturing Market, Sub-Segmentation Of Viral Vector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenoviral Vectors
• Lentiviral Vectors
• Adeno-Associated Viral Vectors (AAV)
• Retroviral Vectors
• 6.8. Global Viral Vectors And Plasmid DNA Manufacturing Market, Sub-Segmentation Of Non-Viral Vector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liposome-Based Vectors
• Polymer-Based Vectors
• Nanoparticle-Based Vectors
• Electroporation-Based Vectors

7. Viral Vectors And Plasmid DNA Manufacturing Market Regional And Country Analysis

• 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Vectors And Plasmid DNA Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Vectors And Plasmid DNA Manufacturing Market

• 8.1. Asia-Pacific Viral Vectors And Plasmid DNA Manufacturing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Vectors And Plasmid DNA Manufacturing Market

• 9.1. China Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 9.2. China Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Vectors And Plasmid DNA Manufacturing Market

• 10.1. India Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Vectors And Plasmid DNA Manufacturing Market

• 11.1. Japan Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 11.2. Japan Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Vectors And Plasmid DNA Manufacturing Market

• 12.1. Australia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Vectors And Plasmid DNA Manufacturing Market

• 13.1. Indonesia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Vectors And Plasmid DNA Manufacturing Market

• 14.1. South Korea Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 14.2. South Korea Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Vectors And Plasmid DNA Manufacturing Market

• 15.1. Western Europe Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 15.2. Western Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Vectors And Plasmid DNA Manufacturing Market

• 16.1. UK Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Vectors And Plasmid DNA Manufacturing Market

• 17.1. Germany Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Vectors And Plasmid DNA Manufacturing Market

• 18.1. France Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Vectors And Plasmid DNA Manufacturing Market

• 19.1. Italy Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Vectors And Plasmid DNA Manufacturing Market

• 20.1. Spain Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Vectors And Plasmid DNA Manufacturing Market

• 21.1. Eastern Europe Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 21.2. Eastern Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Vectors And Plasmid DNA Manufacturing Market

• 22.1. Russia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Vectors And Plasmid DNA Manufacturing Market

• 23.1. North America Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 23.2. North America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Vectors And Plasmid DNA Manufacturing Market

• 24.1. USA Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 24.2. USA Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Vectors And Plasmid DNA Manufacturing Market

• 25.1. Canada Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 25.2. Canada Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Vectors And Plasmid DNA Manufacturing Market

• 26.1. South America Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 26.2. South America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Vectors And Plasmid DNA Manufacturing Market

• 27.1. Brazil Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Vectors And Plasmid DNA Manufacturing Market

• 28.1. Middle East Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 28.2. Middle East Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Vectors And Plasmid DNA Manufacturing Market

• 29.1. Africa Viral Vectors And Plasmid DNA Manufacturing Market Overview
• 29.2. Africa Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Vectors And Plasmid DNA Manufacturing Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Vectors And Plasmid DNA Manufacturing Market Competitive Landscape And Company Profiles

• 30.1. Viral Vectors And Plasmid DNA Manufacturing Market Competitive Landscape
• 30.2. Viral Vectors And Plasmid DNA Manufacturing Market Company Profiles
  • 30.2.1. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Catalent Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Viral Vectors And Plasmid DNA Manufacturing Market Other Major And Innovative Companies

• 31.1. Revvity Inc.
• 31.2. Wuxi Biologics Inc.
• 31.3. BioMarin Pharmaceutical
• 31.4. FUJIFILM Diosynth Biotechnologies
• 31.5. Miltenyi Biotec GmbH
• 31.6. Aldevron LLC
• 31.7. Takara Bio Inc.
• 31.8. Poseida Therapeutics Inc.
• 31.9. RegenxBio Inc.
• 31.10. Cobra Biologics
• 31.11. Finvector Vision Therapies Limited
• 31.12. Batavia Biosciences B.V.
• 31.13. uniQure N.V.
• 31.14. Addgene Inc.
• 31.15. BioNTech IMFS GmbH

32. Global Viral Vectors And Plasmid DNA Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Vectors And Plasmid DNA Manufacturing Market

34. Recent Developments In The Viral Vectors And Plasmid DNA Manufacturing Market

35. Viral Vectors And Plasmid DNA Manufacturing Market High Potential Countries, Segments and Strategies

• 35.1 Viral Vectors And Plasmid DNA Manufacturing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Vectors And Plasmid DNA Manufacturing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Vectors And Plasmid DNA Manufacturing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250423_r33620_Viral_Vectors_And_Plasmid_DNA_Manufacturing_GMR_2025